All News

The FDA refuses to file the sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with papillary disease without carcinoma in situ.

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.

Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.

Results from the phase 3 ENVISION trial suggest UGN-102 could be a non-surgical alternative to TURBT for recurrent low-grade intermediate-risk NMIBC.

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.

No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.

Workplace burnout in medicine and oncology can lead to stress, exhaustion, fatigue, and a lack of interest in work, according to Eric P. Winer, MD.

Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.

IBTR with the 1 mm and 2 mm cutoff found rates found the margin widths were small and not clinically meaningful.

Data from cohort 4 of the phase 2 SunRISe-1 trial demonstrate durable DFS with TAR-200 in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Eric P. Winer, MD, said, “[Health care] has a workforce problem, which is part of the reason why we need to embrace nurse practitioners and PAs or APPs.”

Ninety days of endocrine therapy before surgery could change patient/surgeon preference on concurrent radiation use in those with breast cancer.

The FDA requires additional confirmatory evidence to progress the application for TLX101-CDx in this glioma indication.

Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Results from the phase 2/3 trial also show a favorable OS trend for KN026 with chemotherapy vs placebo with chemotherapy in HER2-positive gastric cancer.

Nogapendekin alfa inbakicept plus BCG led to a CR rate of 71%, with 60% of responders maintaining their response for at least 12 months, in patients with bladder carcinoma in situ.

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.